2JQ Stock Overview
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Gritstone bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.74 |
| 52 Week High | US$3.02 |
| 52 Week Low | US$0.67 |
| Beta | 0.65 |
| 1 Month Change | -14.05% |
| 3 Month Change | -64.87% |
| 1 Year Change | n/a |
| 3 Year Change | -90.29% |
| 5 Year Change | -92.35% |
| Change since IPO | -94.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2JQ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.8% | 1.1% |
| 1Y | n/a | -24.9% | 6.5% |
Return vs Industry: Insufficient data to determine how 2JQ performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 2JQ performed against the German Market.
Price Volatility
| 2JQ volatility | |
|---|---|
| 2JQ Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2JQ's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 2JQ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 231 | Andrew Allen | gritstonebio.com |
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors.
Gritstone bio, Inc. Fundamentals Summary
| 2JQ fundamental statistics | |
|---|---|
| Market cap | €77.49m |
| Earnings (TTM) | -€134.33m |
| Revenue (TTM) | €14.50m |
5.3x
P/S Ratio-0.6x
P/E RatioIs 2JQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2JQ income statement (TTM) | |
|---|---|
| Revenue | US$15.64m |
| Cost of Revenue | US$129.71m |
| Gross Profit | -US$114.07m |
| Other Expenses | US$30.83m |
| Earnings | -US$144.89m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.33 |
| Gross Margin | -729.18% |
| Net Profit Margin | -926.25% |
| Debt/Equity Ratio | 288.8% |
How did 2JQ perform over the long term?
See historical performance and comparison